51st week of 2008 patent applcation highlights part 48 |
Patent application number | Title | Published |
20080312260 | Biological markers predictive of anti-cancer response to kinase inhibitors - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided. | 2008-12-18 |
20080312261 | 4- (4-Bromo-2-Fluoroanilino) -6- Methoxy-7- (1-Methylpiperidin-4-Ylmethoxy) Quinazoline Monohydrate - The present invention relates to a ZD6474 monohydrate, to processes for the preparation of a ZD6474 monohydrate, to pharmaceutical compositions comprising a ZD6474 monohydrate as the active ingredient, to the use of a ZD6474 monohydrate in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to the use of a ZD6474 monohydrate in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, such as cancer, in warm-blooded animals such as humans. | 2008-12-18 |
20080312262 | ARYLOXYALKYLCARBAMATE-TYPE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS - The invention relates to a compound of formula (I): | 2008-12-18 |
20080312263 | PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the use,
| 2008-12-18 |
20080312264 | Process for the production of an abuse-proofed solid dosage form - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a synthetic or natural polymer with a breaking strength of =500 N, characterised in that a corresponding mixture is processed by melt extrusion with the assistance of a planetary-gear extruder. | 2008-12-18 |
20080312265 | Treatment of Drug-Resistant Tumors - A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of drug-resistant tumors and/or for the administration to patients who show polymorphisms in the gene coding for DNA topoisomerase I. | 2008-12-18 |
20080312266 | Steroidal Compounds For Inhibiting Steroid Sulphatase - There is provided a compound having Formula (I) wherein G is H or a substituent, and wherein R | 2008-12-18 |
20080312267 | Diagnosis and Treatment of Diseases Arising from Defects in the Tuberous Sclerosis Pathway - The present invention relates to compositions and methods for identifying abnormalities in TSC signaling pathways. In particular, the present invention relates to methods of diagnosing and treating disorders such as tuberous sclerosis, which are caused by mutations in the TSC genes. The present invention further relates to methods and compositions for treating cancers mediated by TSC signaling disorders. | 2008-12-18 |
20080312268 | Substituted tricyclic piperidone compounds - Substituted tricyclic piperidone derivatives corresponding to Formula I: | 2008-12-18 |
20080312269 | Therapeutic Agents - The present invention relates to 4,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one and 4,5-dihydropyrrolo[3,2-c]pyridin-4-one compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. | 2008-12-18 |
20080312270 | COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION - Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives. | 2008-12-18 |
20080312271 | AZABENZIMIDAZOLYL COMPOUNDS - Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I | 2008-12-18 |
20080312272 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF - The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives of formula (I): | 2008-12-18 |
20080312273 | Quinoline Derivatives Having Vegf Inhibiting Activity - The invention relates to compounds of formula (I) wherein: either any one of G | 2008-12-18 |
20080312274 | Quinoline Derivatives as Neurokinin Receptor Antagonists - The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors, such as schizophrenia. | 2008-12-18 |
20080312275 | Novel Cyanoguanidine Compounds -
Novel pyridyl cyanoguanidine compounds of general formula I (I) wherein R | 2008-12-18 |
20080312276 | 4,5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators - The invention is directed to 4,5-dihydro-(1H)-pyrazole (pyrazoline) derivatives as cannabinoid CB | 2008-12-18 |
20080312277 | Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders - The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. | 2008-12-18 |
20080312278 | Hydroxyquinoline Derivatives - Compounds of the formula I in which X, Y, R | 2008-12-18 |
20080312279 | Compositions for Treating Fragile X and Other Disorders Methods of Use Thereof, and Screening for Compounds for Fragile X and Other Disorders - Methods of screening compounds, active compositions, pharmaceutical compositions, methods of treating disorders, methods of preventing disorders, and kits to screen a library of compounds, are disclosed. | 2008-12-18 |
20080312280 | 3- (4-{ [4- (4-{ [3-(3, 3-Dimethyl-1-Piperidinyl) Propyl] Oxy} Phenyl) -1-Piperidinyl] Carbonyl}-1-Naphthalenyl) Propanoic or Propenoic Acid as H1 and H3 Receptor Antagonists for the Treatment of Inflammatory and/or Allergic Disorders - The present invention relates to a compound of formula (I), or a salt thereof | 2008-12-18 |
20080312281 | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes - Compounds of formula (I), or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes. | 2008-12-18 |
20080312282 | Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme - The present invention relates to compounds of formula (I): | 2008-12-18 |
20080312283 | Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts - Methods to prevent, inhibit, or slow the development of vitrectomy-induced cataracts are disclosed. The methods comprise administering to the eye of a subject a composition comprising an opthalmologically acceptable carrier or diluent and at least one hydroxylamine compound in a therapeutically sufficient amount to prevent, inhibit, or slow the development of a vitrectomy-induced cataract in the subject to which the composition is administered. | 2008-12-18 |
20080312284 | Amorphous Form of 1,2-Dihydropyridine Compound - An amorphous form of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridine-2-one. | 2008-12-18 |
20080312285 | Substituted Indazoles as Inhibitors of Phosphodiesterase Type-Iv - The present invention relates to isoxazoline derivatives of structure Ia, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CNS disorders, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases especially in humans. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and their use as phosphodiesterase (PDE) type IV inhibitors. Formula (Ia) | 2008-12-18 |
20080312286 | Indanone Potentiators of Metabotropic Glutamate Receptors - The present invention is directed to compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. | 2008-12-18 |
20080312287 | Compound and Methods For the Treatment of Cancer and Malaria - Formula (I): Where R | 2008-12-18 |
20080312288 | SOLID FORMS OF 2-CHLORO-4-[1-(4-FLUORO-PHENYL)-2,5-DIMETHYL-1H-IMIDAZOL-4-YLETHYNYL]-PYRIDINE - The present invention relates to the mono-sulfate salt, crystalline forms A and B of the mono-sulfate salt, an amorphous form of the mono-sulfate salt, hemi-sulfate salts, and a crystalline form A of the hemi-sulfate salt of the compound 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine. | 2008-12-18 |
20080312289 | Use of Cni-Sl Formulations for Controlling White Fly - Method of controlling eggs and nymphal stages of whitefly by the spray application of agrochemical formulations containing at least one insecticide from the series of the neonicotinyls, at least one fatty alcohol ethoxylate of the formula (I), at least one solvent from the group consisting of dimethyl sulphoxide, N-methylpyrrolidone and butyrolactone, and, if appropriate, additives. | 2008-12-18 |
20080312290 | Oil Based Suspension Concentrates - Agrochemical formulation comprising at least one room-temperature-solid active substance from the class of the neonicotinoids, at least one room-temperature-solid active substance from the class of the pyrethroids, at least one penetrant, at least one vegetable oil, cyclohexanone, at least one nonionic surfactant and/or at least one anionic surfactant, and one or more additives, process for producing it, and its use for controlling harmful organisms. | 2008-12-18 |
20080312291 | Heterocyclic Gaba-b Modulators - The present invention relates to novel thiazole and oxazole derivatives having a positive allosteric GABA | 2008-12-18 |
20080312292 | Antipruritics - It is intended to provide antipruritics (drugs to control itching, antiitch agents and drugs to stop itching). It is found out that a compound having an agonistic activity to the cannabinoid receptor shows an antipruritics effect. | 2008-12-18 |
20080312293 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them - The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion. | 2008-12-18 |
20080312294 | Tricyclic Compounds, Compositions, and Methods - The present invention is directed to compounds of Formula I: | 2008-12-18 |
20080312295 | Pesticidal Mixtures - Pesticidal mixtures comprising, as active components,
| 2008-12-18 |
20080312296 | Bifunctional synthetic molecules - The synthesis and use of bifunctional molecules to improve the topical and transdermal delivery efficiency of various types of therapeutic agents or agents designed to promote the transdermal delivery of those therapeutic agents either into the skin tissue or into the systemic circulation. Three major classes of molecules are covalently joined as bifunctional substances; chemical vasodilators, passive dermal penetration enhancers and therapeutic or diagnostic drugs. Chemical vasodilators may be delivered into the skin to increasing the blood flow in a tissue that has compromised circulation or they may be used as part of a delivery vehicle to promote the delivery of the drug. Passive dermal penetration enhancers are those chemicals that promote the passive penetration of drugs and other chemicals through the stratum corneum and epidermis of the skin tissue. Drugs and diagnostic agents are the third group of chemicals that are candidates for the linkage of molecules. | 2008-12-18 |
20080312297 | Substituted Oxyguanidines - The present application relates to new substituted oxyguanidines of structure (I) | 2008-12-18 |
20080312298 | Methods for Identification of Modulators of Carm1 Methyl Transferase Activity - This invention relates to CARM1, CARM1 binding pockets, or CARM1-like binding pockets. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. The invention relates to methods of using the structure coordinates to screen for and design compounds that bind to CARM1 protein, complexes of CARM1 protein, homologs thereof, or CARM1-like protein or protein complexes. The invention also relates to crystallizable compositions and crystals comprising a CARM1 protein or homologs thereof. The invention also relates to methods of identifying binders of CARM1 proteins. The invention also relates to methods for determining the intracellular activity of CARM1 methyltransferase and methods for identifying an agent that inhibits the intracellular activity of CARM1 methyltransferase. | 2008-12-18 |
20080312299 | Imidazole Derivatives as Fructose-1,6-Bisphosphatase Inhibitors and Pharmaceutical Compositions Containing Them - Imidazole derivatives of formula (I) wherein R | 2008-12-18 |
20080312300 | Processes for the Preparation of Stable Polymorphic Form I of Ritonavir - The invention relates to processes for the preparation of a polymorphic form of ritonavir. More particularly, it relates to the preparation of a stable polymorphic Form I of ritonavir. The invention also relates to pharmaceutical compositions that include the stable Form I of ritonavir and use of the compositions for treatment of HIV infections in combination with other antiretro viral agents. | 2008-12-18 |
20080312301 | Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof - The invention relates to substituted N-benzo[d]isoxazol-3-yl-amine derivatives of formula (I) wherein R | 2008-12-18 |
20080312302 | Desferasirox Dispersible Tablets - The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet. | 2008-12-18 |
20080312303 | Imidazole Derivatives and Their Use for Modulating the Gabaa Receptor Complex - This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. | 2008-12-18 |
20080312304 | Topical compositions containing metronidazole - Aqueous compositions containing solubilized metronidazole at a concentration of about 0.75% by weight or greater are able to be obtained by using the combination of solubility enhancing agents, first one is niacinamide, second one is urea, and third one is hydroxyalkyl urea. Related methods are also disclosed. | 2008-12-18 |
20080312305 | Imidazoles as Gaba- B Receptor Modulators - The present invention relates to novel imidazole derivatives having a positive allosteric GABA | 2008-12-18 |
20080312306 | POLYMORPHS, SOLVATES, AND HYDRATE OF 5-(4'-FLUORO-2'-OXO-1',2'-DIHYDROSPIRO[CYCLOPROPANE-1,3'-INDOL]-5'-YL)-1-METHYL-1H-PYRROLE-2-CARBONITRILE - Novel polymorph Form II and III, solvate Forms I, II, III, and IV, and the hydrate of 5-(4′-fluoro-2′-oxo-1′,2′-dihydrospiro[cyclopropane-1,3′-indol]-5′-yl)-1-methyl-1H-pyrrole-2-carbonitrile are provided, as are methods for preparing the same. Pharmaceutical compositions and kits containing these novel polymorphs, solvates, and hydrate, and combinations thereof are further provided, as are methods of contraception; treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, hormone-dependent carcinomas; treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder; providing hormone replacement therapy; stimulating food intake; synchronizing estrus; or treating symptoms of premenstrual syndrome using one or more of these polymorphs, solvates, or hydrate. | 2008-12-18 |
20080312307 | MAPK/ERK KINASE INHIBITORS - Compounds are provided for inhibition of MEK that comprise: | 2008-12-18 |
20080312308 | SUBSTITUTED ACETIC ACID DERIVATIVES - The present invention relates generally to substituted acetic acid derivatives and methods of using them. | 2008-12-18 |
20080312309 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA - The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6. | 2008-12-18 |
20080312310 | Compounds, Compositions and Methods - Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed. | 2008-12-18 |
20080312311 | Crystalline forms of 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine - The present invention relates to novel crystalline forms of 3-(2R-tetrahydrofuryl-methyl)-2-thioxanthine. Further the present invention also relates to compositions comprising them and their use in therapy. | 2008-12-18 |
20080312312 | SUBSTITUTED BENZOPYRANS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS - The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof useful as Estrogen Receptor beta agonists for treating Estrogen Receptor beta mediated diseases such as benign prostatic hyperplasia. | 2008-12-18 |
20080312313 | Inhibitors of Ccr9 Activity -
A compound of formula (I), wherein the residues have various meanings, useful as pharmaceuticals. | 2008-12-18 |
20080312314 | Alpha crystalline form of strontium ranelate - Alpha crystalline form of strontium ranelate of formula (I): | 2008-12-18 |
20080312315 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use - Multifunctional compounds are provided that readily crosslink in situ to provide crosslinked biomaterials. The multifunctional compounds contain a single component having at least three reactive functional groups thereon, with the functional groups selected so as to be non-reactive in an initial environment and inter-reactive in a modified environment. Reaction of a plurality of the multifunctional compounds results in a three-dimensional crosslinked matrix. In one embodiment, a first functional group is nucleophilic, a second functional group is electrophilic, and at least one additional functional group is nucleophilic or electrophilic. Methods for preparing and using the multifunctional compounds, and kits including the multifunctional compounds are also provided. Exemplary uses for the multifunctional compounds include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury. | 2008-12-18 |
20080312316 | Chromone Derivatives Useful as Antagonists of Vr1 Receptors - The invention relates to novel heterocyclic compounds of the formula | 2008-12-18 |
20080312317 | 12 MEMBERED-RING MACROLACTAM DERIVATIVES - There provided a 12-membered-ring macrolactam derivative having antitumor activity: A compound represented by Formula (1) or a salt thereof. In this Formula, R | 2008-12-18 |
20080312318 | DEUTERIUM-ENRICHED ESCITALOPRAM - The present application describes deuterium-enriched escitalopram, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2008-12-18 |
20080312319 | Modulation of Bacterial Quorum Sensing with Synthetic Ligands - The present invention provides compounds and methods for modulation of the quorum sensing of bacteria. In an embodiment, the compounds of the present invention are able to act as replacements for naturally occurring bacterial quorum sensing ligands in a ligand-protein binding system; that is, they imitate the effect of natural ligands and produce an agonistic effect. In another embodiment, the compounds of the present invention are able to act in a manner which disturbs or inhibits the naturally occurring ligand-protein binding system in quorum sensing bacteria; that is, they produce an antagonistic effect. The compounds of the present invention comprise N-acylated-homoserine lactones (AHLs) comprised of a wide range of acyl groups. | 2008-12-18 |
20080312320 | Non-dusty, free flowing, storage stable solid composition and a process for its preparation - A solid water dispersible granular composition of pesticide comprising up to 50% of at least one pesticide from pyrethroid class, more particularly a highly viscous liquid pyrethroid insecticide, permethrin, having the properties of excellent dispersibility and suspensibility, as well as the process of preparation of the composition are disclosed. Also the improved storage stability, dispersibility and suspensibility properties are discussed for this granular composition. | 2008-12-18 |
20080312321 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES - Therapeutic compounds are disclosed herein. | 2008-12-18 |
20080312322 | Organic Compounds - A compound of formula (I); in free or pharmaceutically acceptable salt form, where R | 2008-12-18 |
20080312323 | Inhibition of TNF-alpha-Initiated Response - The impact of lipoxin A | 2008-12-18 |
20080312324 | Treatment of lung cells with histone deacetylase inhibitors - Lung disease, such as cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), asthma or acute and chronic bronchitis, can be treated with an oxyamide-containing compound. | 2008-12-18 |
20080312325 | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins - Methods of detecting and treating rapidly growing exogenous cells, such as | 2008-12-18 |
20080312326 | Method for the Prevention and/or Treatment of Neurodegenerative Diseases Characterized by Administering and Ep1 Receptor Antagonist - The present invention relates to the use of EP | 2008-12-18 |
20080312327 | Organic Compositions - Provided is an improved liquid composition for the treatment of surfaces, preferably the skin and/or hair in order to provide a cleaning and/or sanitizing effect thereto, which necessarily comprises: one or more detersive surfactants selected from anionic, nonionic, cationic, and amphoteric surfactants; a first biocidal constituent(s) which provide a biocidal effect in conjunction with at least one or more second biocidal constituent(s) selected from benzoic acid, benzoic acid derivatives and salts thereof or farnesol, one or more pH adjusting constituents, optionally one or more organic solvents, hydrotropes, and further additive constituents, and water. In preferred embodiments the hydrotrope and/or organic solvents are desirably excluded from the compositions, and the composition is thickened. The compositions are particularly useful as a hand wash composition, body wash or shampoo. | 2008-12-18 |
20080312328 | DEUTERIUM-ENRICHED TAMSULOSIN - The present application describes deuterium-enriched tamsulosin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 2008-12-18 |
20080312329 | Nonpeptide Inhibitors of Matrix Metalloproteinases - Disclosed are selective inhibitors of matrix metalloproteinases represented by the following formula (I). | 2008-12-18 |
20080312330 | Methods for Reducing Mortality and Morbidity by Postoperative Administration of a Pharmacologic Cardiovascular Agent - The present invention relates to methods for reducing mortality and cardiovascular morbidity following surgery. In particular, the invention relates to the intensive postoperative administration of a pharmacologic cardiovascular agent to reduce mortality and cardiovascular complications. The invention is illustrated by way of working examples which demonstrate that in patients with, or at risk for, coronary artery disease undergoing major noncardiac surgery, the administration of a 3-adrenergic blocking agent throughout the period of hospitalization: 1) reduces mortality and cardiovascular events following hospital discharge; 2) is safe and well tolerated; and 3) the estimated cost savings in lives more than outweighs the cost of therapy. | 2008-12-18 |
20080312331 | Method of Treating Dailysis-Induced Hypotension - A method is described for the treatment of hypotension, e.g., intra-dialytic hypotension, which is based on the administration to a patient, e.g. a dialysis patient during dialysis, of midodrine or a midodrine metabolite which will increase a lowered blood pressure in the patient or relieve a symptom caused by the dialysis procedure. | 2008-12-18 |
20080312332 | G Protein-Coupled Receptor Antagonist and Its Use for Preventing and Treating Alzheimer's Disease - A method for screening a reagent for treating or preventing Alzheimer's disease or related neurological pathology includes the steps of: (a) activating a receptor and determining a first extent of endocytosis of the receptor, wherein the receptor is a G-protein coupled receptor that associates with presenilin-1; (b) activating the receptor under the same conditions as in step (a), in the presence of a candidate reagent, and determining a second extent of endocytosis of the receptor; (c) determining a difference between the first extent of endocytosis and the second extent of endocytosis; and (d) repeating steps (a)-(c), if the difference is less than a threshold. Uses of receptor antagonists for manufacturing medicaments for treating or preventing Alzheimer's disease or related neurological pathology, wherein the receptor antagonists inhibit endocytosis of a G-protein coupled receptor that associates with presenilin-1 during endocytosis. | 2008-12-18 |
20080312333 | Agent for Preventing/Ameliorating Life Style-Related Diseases Containing Turmeric Essential Oil Component - The present invention has its object to provide an agent for preventing and/or ameliorating life style-related diseases which contains, as an active ingredient, a substance derived from a safe food material having a long history of being eaten as a food and which is capable of being utilized as functional foods such as health foods or functional health foods (specific health foods, functional nutritive foods). | 2008-12-18 |
20080312334 | CYCLOHEXENONE COMPOUNDS FROM ANTRODIA CAMPHORATA TO TREAT AUTOIMMUNE DISEASES - The present invention relates to a compound of | 2008-12-18 |
20080312335 | LIVER PROTECTION COMPOUNDS OF THE CYCLOHEXENONE TYPE FROM ANTRODIA CAMPHORATA - The present invention relates to a compound of | 2008-12-18 |
20080312336 | Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder - The present invention provides preventive and/or therapeutic agents for either one, or both, of a diabetic vascular disorder and a diabetic respiratory disorder comprising, as an active ingredient, a cyclohexenone long chain alcohol compound represented by the following formula (1): | 2008-12-18 |
20080312337 | Anticancer Composition Comprising Obovatol or Obovatal - Disclosed herein is an anticancer composition, comprising obovatol, represented by the following Chemical Formula 1, obovatal, represented by the following Chemical Formula 2, and/or pharmaceutical salts thereof. The composition exhibits the activity of inhibiting the growth of cancer cells and suppressing the expression and activity of matrix metalloproteinases (MMPs), and thus can be useful for the prophylaxis and treatment of cancer as well as for the inhibition of cancer metastasis. | 2008-12-18 |
20080312338 | Formulation - The invention relates to sterile pharmaceutical compositions for parenteral administration which comprise an oil-in-water emulsion in which a free radical scavenging sedative agent dissolved in an omega-3 rich water-immiscible solvent, is emulsified with water and stabilised by means for a surfactant, the composition being suitable either directly or after dilution with a liquid diluent for parenteral administration to a warm-blooded animal; in particular to such compositions comprising propofol, and which optionally further comprise a metal ion chelating agent (such as edetate), and the use of such compositions in improving survival in critically ill patients. | 2008-12-18 |
20080312339 | FLUORINE-SUBSTITUTED ALKYL PHENOL COMPOUNDS AND THEIR USES - The present invention relates to the synthesis of fluorinated forms of alkyl phenol compounds and their subsequent use as pharmaceutical agents. More specifically, alkyl phenol compounds are fluorinated to increase compound volatility such that the compound may be administered to a mammal, such as a human being, by inhalation. The invention also provides an inhaler (or vaporizer), that can be used for administration of the volatile derivatives of fluorine-substituted alkyl phenol compound. Further, different derivatives of fluorine-substituted alkyl phenol compound can be also administered by other routes as described in this document. | 2008-12-18 |
20080312340 | Process for Preparing Dispersions - The invention provides a process for preparing a dispersion of particles, by reducing in particle size at least one component by agitating the component in the presence of (i) a plurality of beads; (ii) a powder; (iii) a surfactant; and (iv) a liquid medium to form a dispersion, wherein the particles are uniformly dispersed in the liquid medium. The invention further provides for the use of the dispersion of particles. | 2008-12-18 |
20080312341 | MONO-, DI- AND POLYOL PHOSPHATE ESTERS IN PERSONAL CARE FORMULATIONS - A hydrophilized personal care formulation, which can be in the form of a hand or body soap (liquid or bar), lipstick, body wash, makeup remover, skin cleaner, hair conditioner, skin or hair moisturizer. The formulation employs an organophosphorus material or a mixture of an organophosphorus material, for example, mono-, di-, and polyol phosphate esters. | 2008-12-18 |
20080312342 | Process for the Production of Diacylglycerol - The present invention provides a process for producing a diacylglycerol, which comprises, reacting triacylglycerol with water and an enzyme preparation to obtain a mixture comprising of diacylglycerol, monoacylglycerol and free fatty acid; removing water content in the mixture by way of dehydration; and separating monoacylglycerol, free fatty acid and residual triacylglycerol by at least one separation method to obtain a high-purity diacylglycerol. An oil or fat composition comprising of diacylglycerol obtained from the said process and phytosteryl esters and/or ferulic acid esters in an amount of from 0.5% to 25% by weight of diacylglycerol is also provided. | 2008-12-18 |
20080312343 | Novel Concentrated Inverse Latex, Process for Preparing It and Industrial Use Thereof - The invention relates to a composition in the form of a positive latex comprising a) between 50 wt. % and 80 wt. % of at least one cross-linked, branched, or linear organic polymer (P), b) between 5 wt. % and 10 wt. % of a water-in-oil (W/O) emulsifying system (S | 2008-12-18 |
20080312344 | DENDRIMERS MULTIVALENTLY SUBSTITUTED WITH ACTIVE GROUPS - The present invention relates to dendrimers being multivalently substituted with active groups, as well as to processes for the preparation thereof and to the use of such multivalent dendrimers. | 2008-12-18 |
20080312345 | Aqueous Film Coating Composition Containing Sodium Alginate and Preparation Thereof - A coating composition comprising sodium alginate and plasticizer, optionally detackifying agents, opacifers and colorants. The coating composition of the present invention may be applied to a pharmaceutical and veterinary tablet, caplets, pellets, granules, neutraceuticals, food, confectionery, seeds, animal feed, fertilizers and pesticide tablets and provides an elegant, glossy, prompt release coating which does not retard the release of active ingredients from the coated substrate. | 2008-12-18 |
20080312346 | Conversion of Lignocellulosic Biomass to Chemicals and Fuels - A method for preparing biomass for slurry processing. The method includes solubilizing the solid material into either a dissolved state or a suspended solid in a liquid phase, and treating the liquid phase to produce chemicals and fuels. | 2008-12-18 |
20080312347 | Production of Hydrocarbons from Natural Gas - A process for producing hydrocarbons from natural gas includes, in a cryogenic separation stage, cryogenically separating the natural gas to produce at least a methane stream and natural gas liquids, in a reforming stage, reforming the methane stream to produce a synthesis gas which includes at least CO and H | 2008-12-18 |
20080312348 | Method and apparatus for steam hydro-gasification with increased conversion times - A method and apparatus for converting carbonaceous material to a stream of carbon rich gas, comprising heating a slurry feed containing the carbonaceous material in a hydrogasification process using hydrogen and steam, at a temperature and pressure sufficient to generate a methane and carbon monoxide rich stream in which the conversion time in the process is between 5 and 45 seconds. In particular embodiments, the slurry feed containing the carbonaceous material is fed, along with hydrogen, to a kiln type reactor before being fed to the fluidized bed reactor. Apparatus is provided comprising a kiln type reactor, a slurry pump connected to an input of the kiln type reactor, means for connecting a source of hydrogen to an input of the kiln type reactor; a fluidized bed reactor connected to receive output of the kiln type reactor for processing at a fluidizing zone, and a source of steam and a source of hydrogen connected to the fluidized bed reactor below the fluidizing zone. Optionally, a grinder can be provided in the kiln type reactor. | 2008-12-18 |
20080312349 | METHOD OF MAKING AND USING MEMBRANE - A process is provided that includes attaching a zwitterion to a polymer or a copolymer, wherein the polymer or copolymer comprises a polyarylene ether or a polyarylene. | 2008-12-18 |
20080312350 | Crosslinked aromatic polymer electrolyte membrane and method for producing same - An aromatic polymer film substrate, or a grafted aromatic polymer film substrate having a monomer introduced therein as graft chains is irradiated with ionizing radiation to impart a crosslinked structure. The aromatic polymer film substrate or the grafted aromatic polymer film substrate, provided with the crosslinked structure, is directly sulfonated to obtain a crosslinked aromatic polymer electrolyte membrane. The crosslinked aromatic polymer electrolyte membrane has low water uptake, high proton conductivity, low methanol permeability, high chemical stability, and excellent mechanical characteristics. A method for producing the crosslinked aromatic polymer electrolyte membrane is also provided. | 2008-12-18 |
20080312351 | Tetraalkylammonium Carboxylate Salts as Trimerization Catalysts for Spray Foam Applications - The present invention provides a method to produce a polyisocyanurate/-polyurethane spray foam using a trimerization catalyst composition having tetraalkylammonium salt of a sterically hindered carboxylic acid or an α,β-unsaturated carboxylic acid. | 2008-12-18 |
20080312352 | Dyes and Dye Mixtures for Dying Polymers, Method for the Production Thereof and Their Use - The present invention relates to dyes of the general formula (1) | 2008-12-18 |
20080312353 | Process for Preparation of High-Molecular-Weight Polyamides - Process for preparation of high-molecular-weight polyamides, which comprises reacting a polyamide A) at a temperature of from 150 to 350° C. with a compound B) which at this reaction temperature liberates isocyanic acid, where the concentration of the amino end groups in the polyamide A) used is greater than or equal to the concentration of the carboxy end groups. | 2008-12-18 |
20080312354 | Removable Radiation Cured Composition And Process For Protecting A Micro-Fluid Ejection Head - There is disclosed a removable radiation cured member suitable for use in protecting a micro-fluid ejection head. Further, a reactant mixture suitable for sealing a micro-fluid ejection head comprising a vinyl-containing oligomer, a filler, and optionally a reactive diluent and/or a photoinitiator is disclosed. | 2008-12-18 |
20080312355 | Composition For Forming Prism Layer And Prism Film Manufactured Using The Same - A composition for forming a prism layer and a prism film manufactured using the same. The composition for forming a prism layer includes a UV-curable monomer A, including a fluorene derivative diacrylate monomer represented by Formula 1 or 2; a UV-curable monomer B, including at least one acrylate monomer; a photoinitiator; and an additive, and thus is excellent in surface strength, adhesion to a substrate film and anti-yellowing properties, with a viscosity suitable for formation of the prism layer. | 2008-12-18 |
20080312356 | Vapor-deposited biocompatible coatings which adhere to various plastics and metal - A method of providing a biocompatible PEG-comprising coating on a substrate, without the use of an underlying adhesion layer. The coating is vapor deposited onto the substrate from a precursor which includes a PEG-derived moiety and an amino silane-containing functional group which reacts with the substrate. The substrate may be metal or plastic, where plastic excludes polyimide and polycarbonate. The substrate may be plasma treated prior to deposition of the PEG-comprising coating. | 2008-12-18 |
20080312357 | COMPOSITION FOR DRY LUBRICANT FILM AND PLAIN BEARING WITH SLIDING LAYER USING THE SAME - The present invention provides a plain bearing having improved bearing properties, especially anti-seizure property, initial conformability and cavitation resistance. According to the present invention, a sliding layer is provided on a surface of a bearing alloy layer comprising of a copper-based or aluminum-based alloy, thereby the sliding layer is so structured that, to a polyamide-imide resin of a main constituent, a polyamide resin is added and mixed under a high shear force to form a polymer-alloyed resin binder, in which 1 to 75% by mass of a solid lubricant is dispersed. The sliding layer can have high toughness and strength, as well as improved anti-seizure property, initial conformability and cavitation resistance. | 2008-12-18 |
20080312358 | Non-Aqueous Pigment Dispersions Containing Specific Dispersion Synergists - A non-aqueous pigment dispersion includes a color pigment, a polymeric dispersant, and a dispersion synergist wherein the molecular weight of the anionic part of the dispersion synergist containing at least one carboxylate anion is smaller than 98% of the molecular weight of the color pigment and that the anionic part of the dispersion synergist has a similarity coefficient SIM of at least 0.5 with the similarity coefficient defined by: | 2008-12-18 |
20080312359 | Thermal Insulation with Thin Phase Change Layer - The present disclosure encompasses provides thermal stabilizer compositions comprising a phase change material admixed with a support material such as a diatomaceous earth, and a nucleator. The present disclosure further encompasses a heat insulation blanket for reducing heat transfer between adjacent spaces, comprising at least two plies of thermoplastic sheet material in superposed relationship and a seal, wherein the seal connects the plies of sheet material to form a cell containing a volume of a thermal stabilizer comprising a phase change material, a support material such as a diatomaceous earth, and a nucleator. | 2008-12-18 |